BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 17178178)

  • 1. Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis.
    Carrillo E; Ahmed S; Goldsmith-Pestana K; Nieto J; Osorio Y; Travi B; Moreno J; McMahon-Pratt D
    Vaccine; 2007 Feb; 25(8):1534-43. PubMed ID: 17178178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis.
    Carrillo E; Crusat M; Nieto J; Chicharro C; Thomas Mdel C; Martínez E; Valladares B; Cañavate C; Requena JM; López MC; Alvar J; Moreno J
    Vaccine; 2008 Mar; 26(15):1902-11. PubMed ID: 18321614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
    Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigenicity of
    Fernández L; Carrillo E; Sánchez-Sampedro L; Sánchez C; Ibarra-Meneses AV; Jimenez MA; Almeida VDA; Esteban M; Moreno J
    Front Immunol; 2018; 9():843. PubMed ID: 29740446
    [No Abstract]   [Full Text] [Related]  

  • 5. Interleukin-12 augments a Th1-type immune response manifested as lymphocyte proliferation and interferon gamma production in Leishmania infantum-infected dogs.
    Strauss-Ayali D; Baneth G; Shor S; Okano F; Jaffe CL
    Int J Parasitol; 2005 Jan; 35(1):63-73. PubMed ID: 15619517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
    Ramos I; Alonso A; Marcen JM; Peris A; Castillo JA; Colmenares M; Larraga V
    Vaccine; 2008 Jan; 26(3):333-44. PubMed ID: 18093705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.
    Schaut RG; Grinnage-Pulley TL; Esch KJ; Toepp AJ; Duthie MS; Howard RF; Reed SG; Petersen CA
    Vaccine; 2016 Oct; 34(44):5225-5234. PubMed ID: 27665354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes.
    Lemesre JL; Holzmuller P; Cavaleyra M; Gonçalves RB; Hottin G; Papierok G
    Vaccine; 2005 Apr; 23(22):2825-40. PubMed ID: 15780731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs.
    Petitdidier E; Pagniez J; Papierok G; Vincendeau P; Lemesre JL; Bras-Gonçalves R
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004614. PubMed ID: 27223609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semi-quantitative analysis of cytokine expression in asymptomatic canine leishmaniasis.
    Chamizo C; Moreno J; Alvar J
    Vet Immunol Immunopathol; 2005 Jan; 103(1-2):67-75. PubMed ID: 15626462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-10 receptor blockade controls the in vitro infectivity of Leishmania infantum and promotes a Th1 activation in PBMC of dogs with visceral leishmaniasis.
    de Oliveira Cardoso JM; de Brito RCF; Costa AFP; Siqueira Mathias FA; Soares Reis LE; Vieira JFP; de Oliveira Aguiar Soares RD; Reis AB; Roatt BM
    Mol Immunol; 2021 Sep; 137():20-27. PubMed ID: 34182228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.
    Fiuza JA; Gannavaram S; Santiago Hda C; Selvapandiyan A; Souza DM; Passos LS; de Mendonça LZ; Lemos-Giunchetti Dda S; Ricci ND; Bartholomeu DC; Giunchetti RC; Bueno LL; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
    Vaccine; 2015 Jan; 33(2):280-8. PubMed ID: 25475955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunology of canine leishmaniasis.
    Barbiéri CL
    Parasite Immunol; 2006 Jul; 28(7):329-37. PubMed ID: 16842269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canine Leishmania vaccines: still a long way to go.
    Gradoni L
    Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and characterization of new Leishmania promastigote surface antigens, LaPSA-38S and LiPSA-50S, as major immunodominant excreted/secreted components of L. amazonensis and L. infantum.
    Bras-Gonçalves R; Petitdidier E; Pagniez J; Veyrier R; Cibrelus P; Cavaleyra M; Maquaire S; Moreaux J; Lemesre JL
    Infect Genet Evol; 2014 Jun; 24():1-14. PubMed ID: 24614507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral blood mononuclear cell supernatants from asymptomatic dogs immunized and experimentally challenged with Leishmania chagasi can stimulate canine macrophages to reduce infection in vitro.
    Rodrigues CA; Batista LF; Teixeira MC; Pereira AM; Santos PO; de Sá Oliveira GG; de Freitas LA; Veras PS
    Vet Parasitol; 2007 Feb; 143(3-4):197-205. PubMed ID: 17045743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis.
    Fujiwara RT; Vale AM; França da Silva JC; da Costa RT; Quetz Jda S; Martins Filho OA; Reis AB; Corrêa Oliveira R; Machado-Coelho GL; Bueno LL; Bethony JM; Frank G; Nascimento E; Genaro O; Mayrink W; Reed S; Campos-Neto A
    Vet Res; 2005; 36(5-6):827-38. PubMed ID: 16120256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against Leishmania infantum infection.
    Ramos I; Alonso A; Peris A; Marcen JM; Abengozar MA; Alcolea PJ; Castillo JA; Larraga V
    Vaccine; 2009 Nov; 27(48):6695-703. PubMed ID: 19747996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein.
    Fernandes AP; Costa MM; Coelho EA; Michalick MS; de Freitas E; Melo MN; Luiz Tafuri W; Resende Dde M; Hermont V; Abrantes Cde F; Gazzinelli RT
    Vaccine; 2008 Oct; 26(46):5888-95. PubMed ID: 18786587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leishmania infantum-specific T cell lines derived from asymptomatic dogs that lyse infected macrophages in a major histocompatibility complex-restricted manner.
    Pinelli E; Gonzalo RM; Boog CJ; Rutten VP; Gebhard D; del Real G; Ruitenberg EJ
    Eur J Immunol; 1995 Jun; 25(6):1594-600. PubMed ID: 7614987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.